PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
From:
Published online 2012 October 19. doi: 10.1371/journal.pone.0047485

Table 5

Subjects with adverse events (AEs) by system organ class and treatment group.
MeDRA SOCaddIb 200 mg HCc 300 mgddI 200 mgHC 600 mgddI 200 mgHC 900 mgddI 400 mgHC 300 mgddI 400 mgHC 600 mgTotal
Subjects/Armn = 12n = 11n = 10n = 12n = 13N = 58d
Subjects with AE, (%)8 (66.7)6 (54.5)4 (40.0)8 (66.7)10 (76.9)36 (62.1)
Blood/Lymph, (%)4 (33.3)1 (9.1)2 (20.0)2 (16.7)4 (30.8)13 (22.4)
Gastrointestinal, (%)2 (18.2)1 (10.0)1 (8.3)2 (15.4)6 (10.3)
General, (%)1 (8.3)1 (1.7)
Infections, (%)4 (33.3)2 (18.2)2 (20.0)1 (8.3)3 (23.1)12 (20.7)
Injury/Poisoning, (%)1 (8.3)1 (1.7)
Investigations, (%)2 (16.7)3 (27.3)2 (20.0)6 (50.0)4 (30.8)17 (29.3)
Musculoskeletal, (%)1 (9.1)1 (10.0)1 (8.3)1 (7.7)4 (6.9)
Nervous System, (%)1 (8.3)1 (10.0)2 (3.4)
Skin, (%)1 (8.3)1 (1.7)
aSOC  = System Organ Class.
bddI  = didanosine.
cHC  = hydroxycarbamide.
dmodified ITT population.